Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
- Publication Information:
Original Publication: London : BioMed Central, [2001-
- Subject Terms:
- Abstract:
Competing Interests: Declarations. Institutional review board statement: This animal experiment protocol was reviewed and approved by the Animal Ethics Committee of Kunming Medical University, and the approval number is kmmu20221422. Consent for publication: Not applicable. Conflict of interest: The authors declare no conflicts of interest, and all the authors have already approved the publication of the manuscript, which is our original unpublished work.
New treatment strategies for ovarian cancer, which is the deadliest female reproductive tract malignancy, are urgently needed. Here, we investigated the anticancer effects of fenbendazole (FBZ), a benzimidazole compound, on the regulation of apoptosis and mitotic catastrophe in A2780 and SKOV3 human epithelial ovarian cancer cells. Functional experiments, including Cell Counting Kit 8 (CCK-8), colony formation, and flow cytometry assays, were conducted to explore the effects of FBZ on the malignant biological behavior of A2780 and SKOV3 cells. RNA sequencing and western blotting were utilized to elucidate the underlying mechanisms by which FBZ affects cell apoptosis. We found that FBZ inhibited the proliferation and promoted the apoptosis of ovarian cancer cells in a dose-dependent manner. Furthermore, we reported the transcriptome profiling of FBZ-treated SKOV3 ovarian cancer cells. In all, 1747 differentially expressed genes (DEGs) were identified, including 944 downregulated and 803 upregulated genes. KEGG enrichment and Reactome enrichment analyses revealed that the DEGs were associated mainly with mitosis- and cell cycle-related pathways. Additionally, we found that FBZ may promote apoptosis via mitotic catastrophe. Finally, oral administration of FBZ inhibited tumor growth in a mouse model of xenograft ovarian cancer. Overall, these findings suggest that FBZ has therapeutic potential for the treatment of ovarian cancer.
(© 2024. The Author(s).)
- References:
Chem Biol Interact. 2024 Sep 1;400:111176. (PMID: 39084502)
Nat Rev Cancer. 2009 Mar;9(3):153-66. (PMID: 19238148)
Cell Mol Biol Lett. 2023 Mar 28;28(1):25. (PMID: 36977989)
Nat Rev Clin Oncol. 2020 Jul;17(7):395-417. (PMID: 32203277)
Mediators Inflamm. 2015;2015:146282. (PMID: 26491220)
Sci Rep. 2018 Aug 9;8(1):11926. (PMID: 30093705)
Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188965. (PMID: 37625527)
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766)
Curr Pharm Des. 2010 Jan;16(1):69-78. (PMID: 20214619)
Int J Mol Sci. 2022 Mar 29;23(7):. (PMID: 35409093)
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32. (PMID: 24078660)
Apoptosis. 2022 Oct;27(9-10):647-667. (PMID: 35849264)
Environ Microbiol. 2015 Apr;17(4):1119-33. (PMID: 24910927)
Chem Biol Interact. 2022 Jul 1;361:109983. (PMID: 35569513)
Kidney Int. 2002 Oct;62(4):1301-13. (PMID: 12234300)
Korean J Physiol Pharmacol. 2022 Sep 1;26(5):377-387. (PMID: 36039738)
Biol Direct. 2021 Dec 9;16(1):25. (PMID: 34886882)
Biomolecules. 2022 Jun 17;12(6):. (PMID: 35740967)
EMBO J. 2006 Jun 7;25(11):2584-95. (PMID: 16675948)
Radiat Oncol. 2011 Nov 17;6:160. (PMID: 22094106)
Cancer Lett. 2019 Jun 1;451:11-22. (PMID: 30862488)
Lancet. 2019 Mar 23;393(10177):1240-1253. (PMID: 30910306)
Cancer Biol Ther. 2014 Sep;15(9):1268-79. (PMID: 24971465)
Vet Med Sci. 2022 May;8(3):966-981. (PMID: 35020278)
Int J Nanomedicine. 2023 May 01;18:2209-2223. (PMID: 37152471)
Toxicol In Vitro. 2018 Feb;46:313-322. (PMID: 29107018)
J Biol Chem. 2012 Aug 31;287(36):30625-40. (PMID: 22745125)
Biol Pharm Bull. 2022;45(2):184-193. (PMID: 35110505)
Molecules. 2019 Jun 07;24(11):. (PMID: 31181622)
J Pharm Pharmacol. 2016 Feb;68(2):208-18. (PMID: 26730435)
Cancer Cell Int. 2001 Nov 23;1(1):1. (PMID: 11983025)
Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221-231. (PMID: 38468501)
Clin Cancer Res. 2002 Sep;8(9):2963-9. (PMID: 12231542)
Phytomedicine. 2019 Sep;62:152973. (PMID: 31177019)
Mol Cell. 2020 Jun 18;78(6):1045-1054. (PMID: 32516599)
Mol Biotechnol. 2006 Mar;32(3):227-48. (PMID: 16632889)
Cell Death Differ. 2008 Jul;15(7):1153-62. (PMID: 18404154)
J Gynecol Oncol. 2023 Sep;34(5):e58. (PMID: 37170725)
Neuroscience. 2014 Jan 3;256:163-9. (PMID: 24183965)
Exp Ther Med. 2017 Feb;13(2):595-603. (PMID: 28352336)
Nature. 1991 May 16;351(6323):242-5. (PMID: 1828290)
- Grant Information:
XDYC-MY-2022-0056 "Xingdian Talent Support Plan" for Outstanding Doctors in Yunnan Province; 202201AY070001-138 the Basic research in Yunnan Province (Kunming Medical University Joint Project); 202201AY070001-162 the Basic research in Yunnan Province (Kunming Medical University Joint Project); 202305AS350020 The innovative research team of Yunnan Province; YNWR-MY-2019-039 Yunnan Province "Ten Thousand People Plan"
- Contributed Indexing:
Keywords: Apoptosis; Fenbendazole; Mitotic catastrophe; Ovarian cancer
- Accession Number:
621BVT9M36 (Fenbendazole)
0 (Antineoplastic Agents)
- Publication Date:
Date Created: 20241230 Date Completed: 20241231 Latest Revision: 20250104
- Publication Date:
20250114
- Accession Number:
PMC11686899
- Accession Number:
10.1186/s12885-024-13361-9
- Accession Number:
39736624
No Comments.